(PharmaNewsWire.Com, September 18, 2019 ) The overall high content screening market is expected to grow from USD 506.7 million in 2016 to USD 909.0 million by 2022, at a CAGR of 10.3% from 2017 to 2022.
The major factors driving the growth of the HTS market include initiatives undertaken by pharmaceutical and biotechnology companies, increasing R&D spending, technological advancements in HTS, and the availability of government funding and venture capital investments.
• By product and service, the reagents & assay kits
• By technology
• By end user
In 2016, the instruments segment accounted for the largest share in the HCS market. The large share of this segment is attributed to advanced automation techniques and high prices of HCS instruments. The cell imaging and analysis systems sub-segment accounted for the largest share of the HCS instruments market and is expected to further dominate the market by 2022.
In 2016, North America dominated the global market. High R&D expenditure, the presence of major pharmaceutical market players, and increasing government support are some of the factors driving the growth of the HCS market in this region.
The prominent players in the global high-content screening market are GE Healthcare (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group (Switzerland), BioTek Instruments Inc. (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
